Carnegie Investment Counsel Sells 14,949 Shares of Novo Nordisk A/S (NYSE:NVO)

Carnegie Investment Counsel decreased its position in Novo Nordisk A/S (NYSE:NVO) by 7.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,545 shares of the company’s stock after selling 14,949 shares during the quarter. Carnegie Investment Counsel’s holdings in Novo Nordisk A/S were worth $17,079,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Massachusetts Financial Services Co. MA lifted its holdings in shares of Novo Nordisk A/S by 2.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock worth $11,061,000 after acquiring an additional 1,860 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Novo Nordisk A/S by 4.1% in the second quarter. Mercer Global Advisors Inc. ADV now owns 204,581 shares of the company’s stock worth $29,202,000 after purchasing an additional 8,030 shares during the last quarter. Argent Trust Co boosted its position in Novo Nordisk A/S by 25.6% during the second quarter. Argent Trust Co now owns 8,958 shares of the company’s stock valued at $1,279,000 after buying an additional 1,824 shares during the period. Blair William & Co. IL grew its stake in shares of Novo Nordisk A/S by 13.2% during the second quarter. Blair William & Co. IL now owns 80,415 shares of the company’s stock valued at $11,478,000 after buying an additional 9,379 shares during the last quarter. Finally, Waterloo Capital L.P. purchased a new position in shares of Novo Nordisk A/S in the second quarter worth about $480,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.4 %

Shares of NVO opened at $83.26 on Friday. Novo Nordisk A/S has a 1-year low of $80.05 and a 1-year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $98.82 and its 200-day moving average price is $117.93. The firm has a market capitalization of $373.61 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 0.92 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.